Last reviewed 2026-05-16 · How we verify

Lantheus Medical Imaging — Portfolio Competitive Intelligence Brief

Lantheus Medical Imaging pipeline: 3 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Portfolio leaders (marketed + Phase 3 / filed)

Therapeutic area mix

• Other · 2
• Cardiovascular · 1
• Metabolic · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

1. · 1 shared drug class
2. 3D Imaging Drug · 1 shared drug class
3. Avid Radiopharms Inc · 1 shared drug class
4. Blue Earth · 1 shared drug class
5. Blue Earth Diagnostics Ltd · 1 shared drug class
6. Cyclomedica · 1 shared drug class
7. Downstate Clincl · 1 shared drug class
8. GE HealthCare · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lantheus Medical Imaging:

• Lantheus Medical Imaging pipeline updates — RSS
• Lantheus Medical Imaging pipeline updates — Atom
• Lantheus Medical Imaging pipeline updates — JSON

Cite this brief

Drug Landscape (2026). Lantheus Medical Imaging — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lantheus-medical-imaging. Accessed 2026-05-16.

Related

• Lantheus Medical Imaging full company profile
• All CI briefs
• Build a custom feed